Herbal medicinal products in a treatment of mastalgia in gynecologic patients


  • А. Г. Кедрова Federal Research and Clinical Center for Specialized Medical Cares and Medical Technologies, Federal Medical and Biological Agency of Russia, Moscow, Russian Federation
  • С. А. Леваков Institute for Advanced Training, Federal Medical and Biological Agency of Russia, Moscow, Russian Federation, Russian Federation




diffuse dyshormonal breast dysplasia, mastalgia, premenstrual syndrome, Vitex agnus-castus, Mastodynon


Implementation of breast cancer screening using digital mammography improved the diagnosis of primary proliferative regressive structural changes in the breast, manifested as diffuse or diffusely-nodal deformations of tissues. Currently, women are significantly more likely to seek medical consultation for damages of the breast that could not be evaluated earlier. This requires the development of special tactics for their treatment and follow-up. Nowadays, searching for prognostic markers and choosing adequate therapy for nodular and diffuse mastopathy are among the most discussed issues in mammology, because up to 25% of all breast cancer cases are diagnosed during the in situ phase. In this article we try to reassess the problem of dyshormonal changes in the breast and develop an optimal approach to their treatment.

The purpose of research was to study data on the effectiveness of the drug Mastodinon® in gynecological patients with diffuse dishormonal breast dysplasia complicated

by mastalgia. The study included 127 women with mastalgia, which were divided into 2 groups: group I included 96 women with cyclic mastalgia, and group II included 31 women with non-cyclic mastalgia. Patients were recommended the herbal drug Mastodynon® 1 tablet 2 times a day for 6 months. Evaluation of the effect was carried out on the subjective sensations of patients and on the objective data of ultrasound or mammography. Only 78 (61.4%) patients were assessed in dynamics according to the results of control examinations performed in the period from the 4th to the 8th month after the start of therapy. The results of the study in the treatment group Mastodynon® was 2.6 times better than in the untreated group: on average by the 6th month of therapy a positive response was observed in 71% of cases in the form of the disappearance or reduction in the mastalgia severity.



How to Cite

Кедрова, А. Г., & Леваков, С. А. (2019). Herbal medicinal products in a treatment of mastalgia in gynecologic patients. REPRODUCTIVE ENDOCRINOLOGY, (48), 77–81. https://doi.org/10.17650/1994-4098-2017-13-4-63-70



Tumors and pretumoral pathology